文档下载 文档下载导航
设为首页 | 加入收藏
搜索 请输入内容:  
 导航当前位置: 文档下载 > 所有分类 > 自然科学 > 生物学 > attributes of glycosylated biopharmaceuticals
侵权投诉

attributes of glycosylated biopharmaceuticals

CoRREsponDEnCE

a

40

b

attributes of glycosylated biopharmaceuticals

5

30

20

10

7

6

5

4

3

2

1

18

22

26

30

34

38

42

46

Isoform number

t (min)

© 2011 Nature America, Inc. All rights reserved.

Figure 1 Comparison of the pre- and post-change Aranesp batches measured by capillary zone electrophoresis. (a) Relative content of the individual isoforms of the pre-change (n = 18) and the post-change (n = 4) batches. (b) Representative electropherograms; peaks are labeled with the isoform number.

attributes of glycosylated biopharmaceuticals

attributes of glycosylated biopharmaceuticals

attributes of glycosylated biopharmaceuticals

attributes of glycosylated biopharmaceuticals

attributes of glycosylated biopharmaceuticals

distribution between two sets of batches (Fig. 1a,b). The batches expiring up to April 2010 showed a higher sialylation rate than the batches expiring after September 2010. The average amount of the more highly sialylated isoform number 5 decreased by an average of 10%, whereas the less sialylated isoforms increased 3% (isoform number 4) and 5% (isoform number 3). However, each of the two groups showed a very high batch-to-batch consistency (Fig. 1a). The magnitude might indicate that this change is a consequence of a manufacturing process change. Indeed, in 2008 the European Medicines Agency approved a major process change of Aranesp based on an extensive comparability exercise4. However, although the time frames are

matching, we have no conclusive evidence that

our data reflect this published process change.Rituxan/Mabthera contains a chimeric IgG1 monoclonal antibody against the B-cell surface antigen CD20 (rituximab) as the active ingredient. It is mainly used in the treatment of B-cell malignancies and rheumatoid arthritis. The glycosylation-dependent Fc effector functions are essential contributors to its therapeutic mode of action and clinical efficacy5,6.

We have characterized commercial batches of Rituxan/Mabthera with expiry dates from September 2007 to October 2011 using glycan mapping, cation exchange chromatography (CEX) and antibody-dependent cellular cytotoxicity (ADCC) in vitro bioactivity (Fig. 2). In 2008, an abrupt change in the quality profile became apparent for batches with expiry dates in 2010 or later. The most obvious difference was found in the amount of the C-terminal lysine and N-terminal glutamine variants when analyzed by cation exchange chromatography (Fig. 2a,b and Supplementary Fig. 2a,c). These variants elute as basic variants after the main peak. The post-change batches contain a much smaller amount of these basic variants whose relative amounts are reduced from ~30–50% to ~10%. It should be noted that lysine and glutamine heterogeneity is common for monoclonal

Rel. content (rel. area %)

attributes of glycosylated biopharmaceuticals

a

attributes of glycosylated biopharmaceuticals

b

c

AD

attributes of glycosylated biopharmaceuticals

CC potency (% of reference)

1401201008060

Expiry date

attributes of glycosylated biopharmaceuticals

attributes of glycosylated biopharmaceuticals

G0 glycan (rel. area %)

G0F-GlcNac G0 G0F Man5

GlcNAc Mannose Fucose Mannose

Expiry datet (min)

Figure 2 Comparison of the different pre- and post-change batches of Rituxan/Mabthera. (a) Exemplary CEX chromatograms. (b) Amount of basic variants of the pre-change (n = 12) and post-change (n = 6) batches as measured by CEX. (c) ADCC potency of the pre-change (n = 11) and post-change (n = 8) batches. (d) Relative amount of the G0 glycan of the pre-change (n = 13) and post-change (n = 11) batches. (e) Exemplary glycan mapping chromatograms. (f) Glycan legend.

nature biotechnology volume 29 number 4 april 2011 311

上一页第2页

你可能喜欢

热门文档

相关文档

站点地图 | 文档上传 | 侵权投诉 | 手机版
本站所有资源均来自互联网,本站只负责收集和整理,均不承担任何法律责任,如有侵权等其它行为请联系我们.
文档下载 Copyright 2013 doc.guandang.net All Rights Reserved.  -  email